| Thor Energy Plc (THR) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$8 |
Thor Energy to Present at H-NAT Conference in Paris
|
13 Nov 2025 9:32AM |
$0.014 |
$0.011 |
fallen by
21.43%
|
|
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$16 |
Nerve Cuff approved for use in US DoD and VA hospitals
|
13 Nov 2025 9:32AM |
$0.105 |
$0.120 |
risen by
14.29%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- NervAlign® Nerve Cuff approved for use in US DoD and VA hospitals
- ReNerve Limited is an Australian company focused on peripheral nerve injury solutions
- Approval allows usage in 51 DoD hospitals and 170 VA centers
- NervAlign® Nerve Cuff shows significant pain reduction post-surgery
- ReNerve received initial and repeat orders from federal facilities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$745 |
Update - Notification of buy-back - RF1
|
13 Nov 2025 9:31AM |
$3.290 |
$3.540 |
risen by
7.60%
|
|
| Humm Group Limited (HUM) ORDINARY FULLY PAID |
Financials |
$355 |
Application for quotation of securities - HUM
|
13 Nov 2025 9:31AM |
$0.620 |
$0.710 |
risen by
14.52%
|
|
| SGH Limited (SGH) ORDINARY FULLY PAID |
Industrials |
$19,495 |
Annual General Meeting Addresses and Presentation
|
13 Nov 2025 9:31AM |
$45.800 |
$47.900 |
risen by
4.59%
|
|
SGH - Price-sensitive ASX Announcement
Full Release
Key Points
- SGH Limited operates in industrial services, energy, and media.
- Record earnings and 20% EBIT CAGR over the past decade.
- Disciplined capital allocation and governance drive value creation.
- Safety improvements implemented after workplace fatalities.
- Focus on infrastructure, construction, mining, and transitional energy.
- Commitment to sustainability and community impact.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genmin Limited (GEN) ORDINARY FULLY PAID |
Materials |
$24 |
Trading Halt
|
13 Nov 2025 9:29AM |
$0.022 |
$0.007 |
fallen by
68.18%
|
|
GEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Genmin Limited requests trading halt as per ASX Listing Rule 17.1.
- The halt is due to a pending announcement regarding capital raising.
- Trading halt to last until 17 November 2025 or until the announcement is made.
- No known reasons against granting the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Artrya Limited (AYA) ORDINARY FULLY PAID |
Health Care |
$490 |
SAPPHIRE Study Expands With Inclusion of Ascension
|
13 Nov 2025 9:29AM |
$3.600 |
$3.100 |
fallen by
13.89%
|
|
AYA - Price-sensitive ASX Announcement
Full Release
Key Points
- Artrya Limited announces Ascension's inclusion in the SAPPHIRE Study.
- Ascension is a major non-profit health system in the U.S.
- The study aims to improve coronary artery disease detection using AI.
- SAPPHIRE Study to start in early 2026.
- Ascension provides significant research and clinical trial capabilities.
- The study will focus on improving care for women with no prior symptoms of coronary artery disease.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Investment Management Ltd (CIW) ORDINARY FULLY PAID |
Financials |
$31 |
Update - Notification of buy-back - CIW
|
13 Nov 2025 9:28AM |
$0.385 |
$0.370 |
fallen by
3.90%
|
|
| Humm Group Limited (HUM) ORDINARY FULLY PAID |
Financials |
$355 |
Cleansing Statement
|
13 Nov 2025 9:28AM |
$0.620 |
$0.710 |
risen by
14.52%
|
|
| CuFe Ltd (CUF) ORDINARY FULLY PAID |
Materials |
$90 |
West Arunta Tenure Update
|
13 Nov 2025 9:28AM |
$0.044 |
$0.052 |
risen by
18.18%
|
|
| ECS Botanics Holdings Ltd (ECS) ORDINARY FULLY PAID |
Health Care |
$9 |
Proposed issue of securities - ECS
|
13 Nov 2025 9:28AM |
$0.008 |
$0.006 |
fallen by
31.25%
|
|
| ECS Botanics Holdings Ltd (ECS) ORDINARY FULLY PAID |
Health Care |
$9 |
ECS successfully completes $1.95m placement
|
13 Nov 2025 9:27AM |
$0.008 |
$0.006 |
fallen by
31.25%
|
|
ECS - Price-sensitive ASX Announcement
Full Release
Key Points
- ECS Botanics Holdings Ltd completed a $1.95 million placement.
- Funds will support international growth, inventory build, and product registrations.
- New shares issued at $0.0065 per share with a free option per share.
- Placement reflects strong market confidence in ECS's strategy.
- Expansion focus on European distribution footprint.
- Options exercisable at $0.011, expiring in 2.5 years.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Antilles Gold Limited (AAU) ORDINARY FULLY PAID |
Materials |
$34 |
Program for Infill Drilling & DFS for La Demajagua Mine
|
13 Nov 2025 9:27AM |
$0.009 |
$0.011 |
risen by
22.22%
|
|
| ANZ Group Holdings Limited (ANZ) ORDINARY FULLY PAID |
Financials |
$123,251 |
Online Meeting Guide and FAQs
|
13 Nov 2025 9:27AM |
$38.850 |
$40.890 |
risen by
5.25%
|
|
| IPH Limited (IPH) ORDINARY FULLY PAID |
Industrials |
$894 |
Annual General Meeting - Withdrawal of Resolution
|
13 Nov 2025 9:27AM |
$3.720 |
$3.420 |
fallen by
8.06%
|
|
| Lycopodium Limited (LYL) ORDINARY FULLY PAID |
Industrials |
$590 |
Lycopodium Sustainability Report 2025
|
13 Nov 2025 9:27AM |
$12.740 |
$14.840 |
risen by
16.48%
|
|
| Diablo Resources Limited (DBO) ORDINARY FULLY PAID |
Materials |
$5 |
Commencement of Trading on OTCQB Market
|
13 Nov 2025 9:26AM |
$0.023 |
$0.022 |
fallen by
4.35%
|
|
DBO - Price-sensitive ASX Announcement
Full Release
Key Points
- Diablo Resources Limited has qualified to trade on the OTCQB market under the symbol 'DBORF'.
- Trading on the OTCQB commenced on 12 November 2025 in the United States.
- The dual listing offers improved trading accessibility and increased liquidity for U.S. investors.
- U.S investors can trade Diablo Resources ordinary shares in U.S. dollars during U.S. market hours.
- The OTCQB listing does not affect trading of Diablo's shares on the ASX, and no new shares have been issued.
- Information disclosed to the ASX will also be available on the OTC Markets platform for U.S. investors.
- Non-Executive Chairman Paul Lloyd emphasized the strategic milestone of making shares accessible to U.S. investors.
- The company aims to accelerate exploration in its U.S. mineral projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$123 |
Results for the Third Quarter of 2025
|
13 Nov 2025 9:26AM |
$6.030 |
$7.770 |
risen by
28.86%
|
|
AVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Anteris Technologies Global Corp. is advancing the PARADIGM Trial to evaluate the DurAVR® THV.
- FDA approval for U.S. recruitment was announced in November 2025.
- First PARADIGM patients were treated in Denmark following Danish regulatory approval in October 2025.
- Anteris is strengthening operational infrastructure and progressing manufacturing scale-up for DurAVR® THV.
- Net operating cash outflows for the nine months ended September 30, 2025, were $59.3 million.
- Research and Development expenses were $16.8 million for the quarter ended September 30, 2025.
- Selling, general, and administrative expenses were $5.8 million for the same period.
- Anteris held $9.1 million of cash and cash equivalents as of September 30, 2025.
- The PARADIGM Trial aims for FDA Premarket Approval and CE Mark approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resouro Strategic Metals Inc (RAU) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$14 |
MOU with RETI for REE Extraction & Processing Collaboration
|
13 Nov 2025 9:25AM |
$0.275 |
$0.320 |
risen by
16.36%
|
|
| Sunrise Energy Metals Limited (SRL) ORDINARY FULLY PAID |
Materials |
$1,373 |
Trading Halt
|
13 Nov 2025 9:25AM |
$4.160 |
$9.560 |
risen by
129.81%
|
|
SRL - Price-sensitive ASX Announcement
Full Release
Key Points
- SRL requests a trading halt on the ASX.
- The halt is related to a capital raising announcement.
- The halt will last until 17 November 2025 or until the announcement is released.
- The trading halt is in accordance with ASX Listing Rule 17.1.
- SRL aims to manage its continuous disclosure obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pengana Global Private Credit Trust (PCX) ORDINARY UNITS FULLY PAID |
Financials |
$234 |
Update - Dividend/Distribution - PCX
|
13 Nov 2025 9:25AM |
$2.000 |
$2.020 |
risen by
1%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$9,917 |
FWP Term Sheets
|
13 Nov 2025 9:24AM |
$13.020 |
$70.060 |
risen by
438.10%
|
|
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$12,350 |
Update - Notification of buy-back - PME
|
13 Nov 2025 9:24AM |
$257.210 |
$118.220 |
fallen by
54.04%
|
|
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$123 |
Quarterly Results Announcement and SEC Form 10-Q
|
13 Nov 2025 9:24AM |
$6.030 |
$7.770 |
risen by
28.86%
|
|
AVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Anteris Technologies Global Corp. is a structural heart company focused on developing medical devices for heart conditions such as aortic stenosis.
- The company’s lead product is the DurAVR® Transcatheter Heart Valve (THV), designed to mimic a healthy human aortic valve.
- The DurAVR® THV uses ADAPT® tissue technology for anti-calcification, and has been FDA-clearance for clinical use worldwide.
- Anteris raised net proceeds of $80.0 million from its initial public offering, primarily for the development of DurAVR® THV.
- Third quarter results showed a net loss of $22,209 thousand, with significant investments in R&D and administrative expenses.
- During the quarter, $52.7 million was allocated to the development of the DurAVR® THV and the PARADIGM Trial preparations.
- The PARADIGM Trial received FDA approval to proceed in November 2025 for evaluating the DurAVR® THV.
- The company reported a decrease in cash reserves, with $9,119 thousand in cash and equivalents as of September 30, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| D3 Energy Limited (D3E) ORDINARY FULLY PAID |
Energy |
$31 |
Investor Presentation - Noosa Mining Conference
|
13 Nov 2025 9:24AM |
$0.450 |
$0.345 |
fallen by
23.33%
|
|